Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON22744
NL-OMON22744
Not yet recruiting
Not Applicable

Hypofractionated irradiation for Prostate cancer.<br>Improving 5-year relapse free survival without increasing toxicity.

Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands Cancer Institute, Amsterdam0 sites800 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate cancer has become the most common non-skin malignancy in men in Western countries. Over recent years the number of diagnosed patients has increased dramatically because of routine prostate-specific antigen (PSA) testing. For a large proportion of prostate cancer patients, external-beam radiotherapy (EBRT) will be the treatment of choice.

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate cancer has become the most common non-skin malignancy in men in Western countries. Over recent years the number of diagnosed patients has increased dramatically because of routine prostate-specific antigen (PSA) testing. For a large proportion of prostate cancer patients, external-beam radiotherapy (EBRT) will be the treatment of choice.
Sponsor
Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands Cancer Institute, Amsterdam
Enrollment
800
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands Cancer Institute, Amsterdam

Eligibility Criteria

Inclusion Criteria

  • •1\. Histologically proven adenocarcinoma of
  • •the prostate

Exclusion Criteria

  • •1\. Pretreatment PSA \>/\= 60 µg/l
  • •2\. Previous irradiation in the pelvic region or radical prostatectomy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III studyProstate cancerCancer
ISRCTN85138529Erasmus Medical Center (The Netherlands)800
Completed
Not Applicable
Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate CancerHigh Risk Prostate Cancer
NCT02107287Sergio Faria105
Completed
Not Applicable
Short Course Radiotherapy for Localized Prostate CancerAdenocarcinoma of Prostate
NCT03518853Tata Medical Center30
Completed
Not Applicable
Hypofractionated Radiotherapy for Prostate CancerProstate Cancer
NCT03851926Consorci Sanitari de Terrassa300
Completed
Phase 2
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)Prostatic Neoplasms
NCT00855647Stanford University99,999